Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

I'm two for two on writing about games set on the moon today, but sometimes that's just how it is! This time around it's about a newly revealed game called Descent of Lunaris, a dungeon-crawling, turn ...

Dr. James McCaffrey presents a complete end-to-end demonstration of the kernel ridge regression technique to predict a single numeric value. The demo uses stochastic gradient descent, one of two ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...